New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:24 EDTMDT, EWEdwards Lifesciences data to boost competitiveness, says Wells Fargo
Wells Fargo believes that data scheduled to be presented on March 30 will show that Edwards' (EW) Sapient XT has advantages over Medtronic's (MDT) CoreCalve, and will help Edwards compete more effectively with Medtronic in the U.S. The firm expects the American College of Cardiology's annual meeting from March 29-31 to boost adoption of TAVR products. It keeps Outperform ratings on both Edwards and Medtronic.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
20:04 EDTMDTMedtronic CEO sees untapped potential in India, Times of India says
Subscribe for More Information
May 20, 2015
09:34 EDTMDTMedtronic announces new data for drug-coated balloon
Subscribe for More Information
07:16 EDTMDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
05:30 EDTEWEdwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve
Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.
May 19, 2015
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
May 18, 2015
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
May 15, 2015
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
May 14, 2015
13:34 EDTMDTMedtronic: Micra transcatheter pacemaker meets initial safety measures in study
Subscribe for More Information
13:31 EDTMDTMedtronic says Evera MRI ICD study meets safety, efficacy endpoints
Subscribe for More Information
09:41 EDTMDTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
May 12, 2015
10:02 EDTMDTMedtronic receives FDA approval and CE Mark for Advance ST cryoballoon
Subscribe for More Information
10:01 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:48 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Edwards Lifesciences to Overweight following the 15% selloff since mid-March. The firm says its confidence in the conversion of the surgical valve replacement market to transcatheter replacement increased significantly at this year's ACC. It adds that its recent field work indicates the TAVR market has accelerated post-ACC. JPMorgan raised its price target for shares to $155 from $147.
06:35 EDTEWEdwards Lifesciences upgraded to Overweight from Neutral at JPMorgan

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use